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Abstract
Background: While antidepressant-induced suicidality is a concern in younger age groups, there
is mounting evidence that these drugs may reduce suicidality in the elderly. Regarding a possible
association between other types of psychoactive drugs and suicide, results are inconclusive.
Sedatives and hypnotics are widely prescribed to elderly persons with symptoms of depression,
anxiety, and sleep disturbance. The aim of this case-control study was to determine whether
specific types of psychoactive drugs were associated with suicide risk in late life, after controlling
for appropriate indications.
Methods: The study area included the city of Gothenburg and two adjacent counties (total 65+
population 210 703 at the start of the study). A case controlled study of elderly (65+) suicides was
performed and close informants for 85 suicide cases (46 men, 39 women mean age 75 years) were
interviewed by a psychiatrist. A population based comparison group (n = 153) was created and
interviewed face-to-face. Primary care and psychiatric records were reviewed for both suicide
cases and comparison subjects. All available information was used to determine past-month mental
disorders in accordance with DSM-IV.
Results: Antidepressants, antipsychotics, sedatives and hypnotics were associated with increased
suicide risk in the crude analysis. After adjustment for affective and anxiety disorders neither
antidepressants in general nor SSRIs showed an association with suicide. Antipsychotics had no
association with suicide after adjustment for psychotic disorders. Sedative treatment was
associated with an almost fourteen-fold increase of suicide risk in the crude analyses and remained
an independent risk factor for suicide even after adjustment for any DSM-IV disorder. Having a
current prescription for a hypnotic was associated with a four-fold increase in suicide risk in the
adjusted model.
Conclusion: Sedatives and hypnotics were both associated with increased risk for suicide after
adjustment for appropriate indications. Given the extremely high prescription rates, a careful
evaluation of the suicide risk should always precede prescribing a sedative or hypnotic to an elderly
individual.
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Background
The use of psychotropic drugs among the elderly is high
[1-3] and health risks associated with these drugs are a
topic of public health concern. Increased risk for fall acci-
dents [4,5], adverse drug reactions [6], drug related mor-
bidity [7] and unfavourable interactions with other
medication [8] have been emphasized in the literature.
While the induction of suicidality is a concern in younger
age groups [9], there is increasing evidence that antide-
pressants may be beneficial in the prevention of suicide
late in life [10-15]. Regarding a possible association
between other types of psychoactive drugs (sedatives, hyp-
notics, antipsychotics) and suicide, results are inconclu-
sive [16-18]. Sedatives and hypnotics are widely
prescribed to elderly persons with symptoms of depres-
sion, anxiety, and sleep disturbance. They are regularly
detected in post-mortem analyses of elderly suicide vic-
tims, and often implicated in lethal overdoses in Sweden
[19].
The elderly consume more psychotropics than any other
age group in Sweden [20]. There have been substantial
changes in the sales of psychotropic drugs to persons aged
65 and above over the last fifteen years. While sales of
antipsychotics (Figure 1a) and sedatives (Figure 1b)
decreased by almost 50% during this time period, sales of
hypnotics remained extremely high (Figure 1c). Sales rates
are particularly high in the older elderly, with Defined
Daily Dosages (DDD)/1000 inhabitants and day as high
as 165 in women and 120 in men (Figure 1c). SSRIs were
introduced in Sweden in 1990 and antidepressant sales
have seen a near five-fold increase since that time (Figure
1d.)
Given the high psychotropic prescription rates and the
high suicide rates in this age group it would be appropri-
ate to examine whether different types of psychotropic
drugs are associated with increased suicide risk. When
testing for a possible association, it is important to rule
out confounding by indication. However, studies that
include detailed evaluation of psychiatric symptoms in
elderly suicides and population-based controls are lack-
ing. The aim of the current study was thus to determine
whether different types of psychotropic drugs were associ-
ated with increased risk of suicide in persons aged 65 years
and above after adjustment for appropriate indications.
Methods
One hundred consecutive cases of suicide among persons
aged 65 years and above who underwent necropsy at the
Gothenburg Institute of Forensic Medicine were reviewed.
Close informants for 85 suicide cases (46 men, 39
women, mean age 75 years) accepted to participate in an
interview with a psychiatrist (MW). We have previously
shown that the study cases were representative of all sui-
cides among persons age 65 and above in the catchment
area during the study period; antidepressants and/or lith-
ium were detected at post-mortem analysis in 38% of the
study cases and 40% of the 100 suicides (65+) evaluated
at the Forensic Institute during the study period [21]. The
study area included the city of Gothenburg and two adja-
cent counties (total 65+ population 210 703 at the start of
the study).
In order to create a population comparison group, two
people with the same sex, year of birth and zip code as
each suicide case were randomly selected from the tax reg-
ister. If a potential comparison person declined participa-
tion, another was invited (up to eight per case). In all, 240
people were invited to take part in the study and 153 par-
ticipated (84 men, 69 women). Comparison subjects were
interviewed face-to-face, using the same questionnaire.
Primary care and psychiatric records were reviewed for
suicide cases and comparison subjects. All available infor-
mation was used to determine past-month mental disor-
ders in accordance with DSM-IV [21].
Ongoing prescriptions were classified according to the
Anatomical Therapeutic Chemical (ATC) classification
[22]. For the purpose of this study the following drugs
were classified as sedatives: diazepam, alprazolam, bus-
pirone, hydroxizine and dixyrazine. These were classified
as hypnotics: flunitrazepam, nitrazepam, zopiclone,
zolpidem, oxazepam, levomepromazine, propiomazine
and alimemazine. Dixyrazine is a neuroleptic, but here
classified as sedative in accordance with its main clinical
use. Levomepromazine, a neuroleptic and alimemazin, an
antihistamine were both included in the hypnotic group
because they are prescribed in Sweden to elderly with
sleep disturbance.
Ethics
The study was approved by the Ethics Committee at the
Faculty of Medicine, Gothenburg University.
Statistics
Crude odds ratios for suicide were calculated for the dif-
ferent classes of psychotropic drugs with bivariate logistic
regression. In a second set of analyses, odds ratios were
adjusted for age, sex and appropriate indications (see
footnote Table 1) using multivariate logistic regression.
Results
Psychotropic drugs were widely prescribed to the suicide
cases and all drug types were associated with suicide in the
unadjusted analyses (Table 1). Antidepressants were pre-
scribed to 40% of the cases at the time of the suicide. Anti-
depressant medication was associated with a ten-fold
increase in suicide risk in the initial analysis. However,
after adjustment for affective disorders and anxiety disor-BMC Geriatrics 2009, 9:20 http://www.biomedcentral.com/1471-2318/9/20
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The sales of psychotropic drugs 1990–2005 among elderly in Sweden Figure 1
The sales of psychotropic drugs 1990–2005 among elderly in Sweden.
 A. Sales of neuroleptics (N05A) 1990-2005 among elderly in Sweden
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B. Sales of sedatives (N05B) 1990-2005 among elderly in Sweden
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C. Sales of hypnotics (N05C) 1990-2005 among elderly in Sweden
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D. Sales of antidepressants (N06A) 1990-2005 among elderly in 
Sweden
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ders, neither antidepressants in general nor SSRIs in par-
ticular showed an association with suicide.
Antipsychotics were prescribed to one tenth of the suicide
group at the time of death. Only 3% of those in the com-
parison group had a prescription for an antipsychotic.
Antipsychotic medication was associated with increased
suicide risk in the initial analyses, but the association did
not remain after adjustment for psychotic disorder.
While sedative use was uncommon among persons in the
control group, over a third of the suicide cases were pre-
scribed sedatives at the time of death. A prescription for a
sedative was associated with an almost twelve-fold
increase of suicide risk after adjustment for anxiety disor-
ders (OR 11.8 C.I. 4.6–30.6). As sedatives may be indi-
cated for anxious elderly with other types of mental
disorder (depression, psychosis) a second model was con-
structed which adjusted for any DSM IV disorder. Sedative
treatment remained an independent four-fold risk factor
for suicide even in the fully adjusted model (Table 1).
Hypnotics were the most widely prescribed drug type in
both cases and controls. Half of the suicide cases had a
prescription for a hypnotic at the time of the suicide. Hyp-
notics were prescribed to one tenth of the comparison
group. A prescription for a hypnotic drug was associated
with a ten-fold increase in suicide risk in the crude analy-
sis. As sleep disturbance may occur in most psychiatric
disorders, the final model was adjusted for any Axis I dis-
order. Having a current hypnotic prescription was associ-
ated with a four-fold increase in suicide risk in this
adjusted model.
As interactions between psychoactive drugs and alcohol
may trigger impulsive behaviour, we wanted to test
whether suicide victims who used sedatives/hypnotics
were more likely to have a positive post-mortem test for
alcohol. For hypnotic users, 11 out of 47 cases had a pos-
itive test for alcohol compared to 14 out of 35 for non-
users (p = 0.146, Fisher's exact test). For sedative users, 8
out of 31 had positive registration for alcohol compared
to 17 out of 51 for non-users (p = 0.622, Fisher's exact
test).
Discussion
We found a four-fold increased suicide risk among elderly
using sedatives and/or hypnotics after adjustment for
appropriate indications. A recent Canadian register-based
study showed a similar odds ratio [23], but it should be
noted that those results pertained specifically to use of
benzodiazepines, and diagnoses were based on physi-
cians claims files. Our finding is at odds with that of Barak
and colleagues [18] who compared rates of benzodi-
azepine prescription in elderly patients with major
depression who did/did not attempt suicide. The propor-
tion with benzodiazepines was larger in the group that did
not attempt suicide. Several methodological differences
may help to explain the conflicting results. First, the out-
come variable in the study by Barak and colleagues was
attempted rather than completed suicide. Second, con-
trols in that study were psychiatric patients; our study
employed face-to-face interviews with individuals ran-
domly selected from the underlying population. Third,
the proportion of women was greater in the Barak study.
Women tend to have higher rates of sedative use than
men, and men higher suicide rates than women.
One possible explanation for the observed increase in sui-
cide risk associated with sedatives and hypnotics in our
study may be that these drugs trigger aggressive behaviour
[24]. Further, interactions between benzodiazepines and
alcohol may intensify impulsive tendencies, thereby
increasing risk of suicide. We have previously reported
that 29% of the suicide cases in the current study had a
positive post-mortem test for alcohol [25]. However, pro-
portions a positive post-mortem test for alcohol were sim-
ilar in suicide cases both with and without sedatives/
hypnotics, indicating that interaction with alcohol cannot
fully explain the observed increase in risk. Another partial
explanation might be that persons with prescriptions for
these drugs have ready access to a suicide method. Availa-
Table 1: Psychotropic drugs prescribed to elderly suicide cases (n = 85) and population controls (N = 153). Odds ratios and 95% 
confidence intervals.
Type of drug prescribed Cases
n (%)
Controls
n (%)
OR(95% CI)a OR(95% CI)b
Any antidepressant 34 (40) 9 (6) 10.7 (4.8–23.8) 0.9 (0.2–3.2)
SSRIs 23 (27) 8 (5) 6.7 (2.9–15.9) 0.8 (0.2–2.9)
Antipsychotics 9 (11) 4 (3) 4.4 (1.3–14.8) 2.7 (0.8–10.1)
Sedatives 31 (36) 6 (4) 14.1 (5.6–35.6) 4.4 (1.3–15.2)
Hypnotics 48 (56) 16 (10) 10.8 (5.4–21.5) 4.2 (1.6–11.0)
a Unadjusted
b Adjusted for age, sex and indication. Antidepressants adjusted for affective and anxiety disorders, antipsychotics adjusted for psychotic disorders, 
sedatives and hypnotics adjusted for any DSM IV Axis I disorder.BMC Geriatrics 2009, 9:20 http://www.biomedcentral.com/1471-2318/9/20
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bility of suicide methods increases suicide risk [26]. The
current study design does not allow us to tease out the
contribution of availability of suicide means on suicide
risk. Suicide methods vary widely in different cultural set-
tings. It would be of interest to test whether sedatives and
hypnotics are associated with increased late-life suicide
risk even in settings where other suicide methods, such as
hanging or shooting are more common.
The finding that sedatives and hypnotics were associated
with increased suicide risk does not in itself imply causal-
ity. It is possible that these drugs are merely markers for
some other factor related to suicide risk, such as somatic
illness, functional disability, alcohol use disorder, inter-
personal problems, lack of social network [27] and sleep
disturbance [28]. Persons with these problems might be
more likely to seek health care and perhaps more likely to
receive prescriptions for psychotropic drugs.
To the best of our knowledge, this is the first study to
examine use of psychotropic drugs in elderly suicides and
matched population controls who have been subjected to
a detailed evaluation of psychiatric symptoms. We did not
find support for the hypothesis that SSRIs increase suicide
risk in the elderly, after controlling for indication. Taken
together with previous observations from ecological stud-
ies [10-13], from retrospective analyses of patient records
[18] and register studies [14], this is important informa-
tion for the clinician, who might be less inclined to pre-
scribe antidepressants in the aftermath of the "black box
warning" that was issued regarding risks in adolescents
[29].
Strengths and limitations
A major strength of this study was the inclusion of
detailed psychopathological data which eliminated issues
of confounding by indication. Study cases were represent-
ative of all suicides in the catchment area [21]. Major lim-
itations include small numbers and the fact that diagnoses
of the suicide victims are based on data accrued by proxy
interviews. However, there is evidence that suicide studies
based on proxy interviews with next of kin (so-called "psy-
chological autopsies") provide reliable diagnoses [30].
Further, medical records were readily available for cases
and controls, and these were authored by physicians who
were "blind" to the suicide outcome. Another methodo-
logical concern was that the participation rate for the com-
parison subjects was lower (64%) than that of the suicide
informants (85%). Potential comparison persons with
mental illness and psychotropic drug treatment might be
less likely to participate, which would result in inflated
odds ratios.
Implications for the clinician
While antidepressant prescription was not an independ-
ent predictor of suicide risk, it is noteworthy that 40% of
the elderly cases committed suicide despite prescribed
treatment for affective illness. Treatment failure cannot be
ascribed to lack of adherence to antidepressants, as we
have previously shown that antidepressants were detected
at post-mortem screening to a large degree [21]. As
pointed out by Szanto and colleagues [31], there is a need
for intensive treatment and follow-up of the depressed
and suicidal elderly. In the present study, sedatives and
hypnotics were related to increased risk for late life sui-
cide. Clinicians need to be aware of this as these drugs are
widely prescribed to the elderly. A careful evaluation of
the suicide risk should be carried out when an elderly per-
son presents with symptoms of anxiety and sleep distur-
bance.
Conclusion
In conclusion sedatives and hypnotics were both associ-
ated with increased risk for suicide after adjustment for
appropriate indications. Given the extremely high pre-
scription rates, a careful evaluation of the suicide risk
should always precede prescribing a sedative or hypnotic
to an elderly individual.
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